Biocon Biologics sees Biopharma SHAKTI as major boost for India’s biosimilar ambitions

India's biopharmaceutical sector receives a significant boost with the Union Budget's ₹10,000 crore Biopharma SHAKTI programme. This initiative aims to enhance domestic manufacturing and innovation capabilities. Industry leaders believe it will help India build globally competitive biologics and biosimilar strengths. The programme focuses on innovation, global scale, and regulatory improvements.